Psychometric properties of the patient health questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients

Changsu Han; Chi Un Pae; Ashwin A. Patkar; Prakash S. Masand; Ki Woong Kim; Sook Haeng Joe; In Kwa Jung

doi:10.1176/appi.psy.50.6.580

Psychometric properties of the patient health questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients

Changsu Han, Chi Un Pae, Ashwin A. Patkar, Prakash S. Masand, Ki Woong Kim, Sook Haeng Joe, In Kwa Jung

Research output: Contribution to journal › Article › peer-review

95 Citations (Scopus)

Abstract

Background: About 2% to 5% of all primary-care patients have a somatization disorder, and somatic symptoms are strongly associated with comorbid depression and anxiety disorders. Objective: The authors evaluated the validity of the 15-item Somatization module of the Patient Health Questionnaire (PHQ-15) among psychiatric outpatients. Method: The PHQ-15 was administered to patients with somatic complaints; it was compared with the Beck Depression Inventory (BDI) and the General Health Questionnaire-12 (GHQ-12). Fifty-seven Korean subjects completed the survey. Results: The PHQ-15 exhibited significant internal consistency, and test-retest reliability. Convergent validity with the BDI and GHQ-12 were positive. Conclusion: These results indicate that the Korean version of the PHQ-15 is appropriate for measuring the severity of somatic symptoms in a psychiatric outpatient setting.

Original language	English
Pages (from-to)	580-585
Number of pages	6
Journal	Psychosomatics
Volume	50
Issue number	6
DOIs	https://doi.org/10.1176/appi.psy.50.6.580
Publication status	Published - 2009
Externally published	Yes

Bibliographical note

Funding Information:
Dr. Han has received research support from a Korea Research Foundation Grant ( MOEHRD ; KRF-2007–013-E00033 ) and from the Research Foundation of Korea Neuropsychiatric Association (2004 Jisan Lee SeJong Cultural Psychiatry Fund). Dr. Pae has received research support from GlaxoSmithKline. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser, and is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from NIH, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer, and Specialty, Inc., Organon, Jazz Pharmaceuticals, and Pfizer. Dr. Masand is a consultant for Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest laboratories Inc., GlaxoSmithKline, i3CME, Janssen Pharmaceutica, Jazz Pharmaceuticals, Organon, Pfizer, Inc., Targacept Inc., and Wyeth Pharmaceuticals, and is on the speaker's bureau of Astra-Zeneca, Bristol Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., and Wyeth Pharmaceuticals; has received research support from AstraZeneca, Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceutica, and Wyeth Pharmaceuticals.

ASJC Scopus subject areas

Arts and Humanities (miscellaneous)
Applied Psychology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1176/appi.psy.50.6.580

Cite this

@article{459f89a84ce84c7db31820fa576d36ae,

title = "Psychometric properties of the patient health questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients",

abstract = "Background: About 2% to 5% of all primary-care patients have a somatization disorder, and somatic symptoms are strongly associated with comorbid depression and anxiety disorders. Objective: The authors evaluated the validity of the 15-item Somatization module of the Patient Health Questionnaire (PHQ-15) among psychiatric outpatients. Method: The PHQ-15 was administered to patients with somatic complaints; it was compared with the Beck Depression Inventory (BDI) and the General Health Questionnaire-12 (GHQ-12). Fifty-seven Korean subjects completed the survey. Results: The PHQ-15 exhibited significant internal consistency, and test-retest reliability. Convergent validity with the BDI and GHQ-12 were positive. Conclusion: These results indicate that the Korean version of the PHQ-15 is appropriate for measuring the severity of somatic symptoms in a psychiatric outpatient setting.",

author = "Changsu Han and Pae, {Chi Un} and Patkar, {Ashwin A.} and Masand, {Prakash S.} and Kim, {Ki Woong} and Joe, {Sook Haeng} and Jung, {In Kwa}",

note = "Funding Information: Dr. Han has received research support from a Korea Research Foundation Grant ( MOEHRD ; KRF-2007–013-E00033 ) and from the Research Foundation of Korea Neuropsychiatric Association (2004 Jisan Lee SeJong Cultural Psychiatry Fund). Dr. Pae has received research support from GlaxoSmithKline. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser, and is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from NIH, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer, and Specialty, Inc., Organon, Jazz Pharmaceuticals, and Pfizer. Dr. Masand is a consultant for Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest laboratories Inc., GlaxoSmithKline, i3CME, Janssen Pharmaceutica, Jazz Pharmaceuticals, Organon, Pfizer, Inc., Targacept Inc., and Wyeth Pharmaceuticals, and is on the speaker's bureau of Astra-Zeneca, Bristol Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., and Wyeth Pharmaceuticals; has received research support from AstraZeneca, Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceutica, and Wyeth Pharmaceuticals. ",

year = "2009",

doi = "10.1176/appi.psy.50.6.580",

language = "English",

volume = "50",

pages = "580--585",

journal = "Psychosomatics",

issn = "0033-3182",

publisher = "American Psychiatric Publishing Inc.",

number = "6",

}

TY - JOUR

T1 - Psychometric properties of the patient health questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients

AU - Han, Changsu

AU - Pae, Chi Un

AU - Patkar, Ashwin A.

AU - Masand, Prakash S.

AU - Kim, Ki Woong

AU - Joe, Sook Haeng

AU - Jung, In Kwa

N1 - Funding Information: Dr. Han has received research support from a Korea Research Foundation Grant ( MOEHRD ; KRF-2007–013-E00033 ) and from the Research Foundation of Korea Neuropsychiatric Association (2004 Jisan Lee SeJong Cultural Psychiatry Fund). Dr. Pae has received research support from GlaxoSmithKline. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser, and is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from NIH, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer, and Specialty, Inc., Organon, Jazz Pharmaceuticals, and Pfizer. Dr. Masand is a consultant for Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest laboratories Inc., GlaxoSmithKline, i3CME, Janssen Pharmaceutica, Jazz Pharmaceuticals, Organon, Pfizer, Inc., Targacept Inc., and Wyeth Pharmaceuticals, and is on the speaker's bureau of Astra-Zeneca, Bristol Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., and Wyeth Pharmaceuticals; has received research support from AstraZeneca, Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceutica, and Wyeth Pharmaceuticals.

PY - 2009

Y1 - 2009

N2 - Background: About 2% to 5% of all primary-care patients have a somatization disorder, and somatic symptoms are strongly associated with comorbid depression and anxiety disorders. Objective: The authors evaluated the validity of the 15-item Somatization module of the Patient Health Questionnaire (PHQ-15) among psychiatric outpatients. Method: The PHQ-15 was administered to patients with somatic complaints; it was compared with the Beck Depression Inventory (BDI) and the General Health Questionnaire-12 (GHQ-12). Fifty-seven Korean subjects completed the survey. Results: The PHQ-15 exhibited significant internal consistency, and test-retest reliability. Convergent validity with the BDI and GHQ-12 were positive. Conclusion: These results indicate that the Korean version of the PHQ-15 is appropriate for measuring the severity of somatic symptoms in a psychiatric outpatient setting.

AB - Background: About 2% to 5% of all primary-care patients have a somatization disorder, and somatic symptoms are strongly associated with comorbid depression and anxiety disorders. Objective: The authors evaluated the validity of the 15-item Somatization module of the Patient Health Questionnaire (PHQ-15) among psychiatric outpatients. Method: The PHQ-15 was administered to patients with somatic complaints; it was compared with the Beck Depression Inventory (BDI) and the General Health Questionnaire-12 (GHQ-12). Fifty-seven Korean subjects completed the survey. Results: The PHQ-15 exhibited significant internal consistency, and test-retest reliability. Convergent validity with the BDI and GHQ-12 were positive. Conclusion: These results indicate that the Korean version of the PHQ-15 is appropriate for measuring the severity of somatic symptoms in a psychiatric outpatient setting.

UR - http://www.scopus.com/inward/record.url?scp=73349084615&partnerID=8YFLogxK

U2 - 10.1176/appi.psy.50.6.580

DO - 10.1176/appi.psy.50.6.580

M3 - Article

C2 - 19996228

AN - SCOPUS:73349084615

SN - 0033-3182

VL - 50

SP - 580

EP - 585

JO - Psychosomatics

JF - Psychosomatics

IS - 6

ER -

Psychometric properties of the patient health questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this